Cuorips Inc. (4894) AI Stock Analysis

• Market Cap: ¥55.07B
• Dividend Yield: N/A
• Average Volume (3M): 107.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 1242.62%
• EPS Growth: 2.56%
• Country: JP
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -24.69
• Shares Outstanding: 8,247,466
• 10 Day Avg. Volume: 98,200
• 30 Day Avg. Volume: 107,556
• PEG Ratio: 16.56
• Price to Book (P/B): 12.03
• Price to Sales (P/S): 379.55
• P/FCF Ratio: -74.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 33 Underperform
• Price Target: ―

Cuorips Inc.'s overall stock score is hindered by significant financial performance issues, including revenue volatility and operational losses. Although the company benefits from strong cash reserves and no debt, these strengths are overshadowed by negative profit margins and cash flow challenges. The technical analysis shows a bearish trend, while valuation metrics indicate caution due to a negative P/E ratio. The absence of earnings call insights and notable corporate events leaves the stock's future somewhat uncertain.

Cuorips Inc. Business Overview & Revenue Model

Company Description

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Cuorips Inc. generates revenue through the development and commercialization of regenerative medicine products targeting cardiac diseases. The company makes money by licensing its proprietary technologies and therapies to pharmaceutical and biotechnology companies. Additionally, Cuorips Inc. may receive funding through collaborative research agreements and partnerships with healthcare institutions and academic entities. Revenue streams could also include milestone payments and royalties from successfully developed and marketed therapies. The company's earnings are significantly influenced by its ability to advance its pipeline products through clinical trials and secure regulatory approvals.

Cuorips Inc. Financial Statement Overview

Summary

Cuorips Inc. shows potential due to strong cash reserves and no debt, yet it faces substantial profitability and cash flow challenges. The company's revenue volatility and negative profit margins indicate a need for strategic changes to improve financial stability and growth prospects. While equity levels are sound, operational losses remain a concern.

Income Statement

Cuorips Inc. has experienced significant revenue volatility, with a marked decline in revenue over the past year. Despite generating gross profit, the company is struggling with substantial negative EBIT and net income figures, indicating heavy operational losses. The EBIT and EBITDA margins are negative, reflecting ongoing profitability challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with no debt, reflected in a solid equity ratio. However, the absence of debt financing may limit financial flexibility. While the return on equity is negative due to the net losses, the high cash reserves provide a cushion against short-term liabilities.

Cash Flow

Cuorips Inc. is facing negative cash flow from operations and free cash flow, indicating cash burn. However, the financing activities have significantly boosted cash reserves. The free cash flow to net income ratio is unfavorable, highlighting ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	260.31M	175.21M	23.10M	38.28M	13.91M	220.00K
Gross Profit	119.12M	91.56M	9.63M	21.01M	10.65M	138.00K
EBITDA	-570.19M	-565.32M	-518.00M	-371.78M	-280.40M	-221.17M
Net Income	-652.25M	-644.34M	-632.18M	-452.08M	-375.34M	-307.83M
Balance Sheet
Total Assets	5.75B	5.74B	6.18B	3.59B	4.04B	4.36B
Cash, Cash Equivalents and Short-Term Investments	4.85B	4.79B	5.58B	2.94B	3.34B	3.54B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	324.59M	211.91M	200.96M	133.79M	149.36M	141.95M
Stockholders Equity	5.42B	5.53B	5.98B	3.45B	3.90B	4.22B
Cash Flow
Free Cash Flow	0.00	-892.81M	-487.01M	-412.18M	-249.45M	-950.97M
Operating Cash Flow	0.00	-812.62M	-451.06M	-401.61M	-220.76M	-282.80M
Investing Cash Flow	0.00	-119.99M	-35.00M	-8.97M	-28.44M	-670.21M
Financing Cash Flow	0.00	145.11M	3.13B	10.69M	48.54M	3.77B

Cuorips Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6430.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Negative. The current price of 6430 is below the 20-day moving average (MA) of 6572.50, below the 50-day MA of 6949.80, and below the 200-day MA of 6466.50, indicating a bearish trend. The MACD of -131.26 indicates Negative momentum. The RSI at 42.80 is Neutral, neither overbought nor oversold. The STOCH value of 36.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4894.

Cuorips Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7774	58 Neutral	¥18.80B	―	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4889	51 Neutral	¥24.24B	383.98	―	―	-27.00%	―
4599	47 Neutral	¥16.96B	-8.77	―	―	―	5.58%
4593	41 Neutral	¥53.92B	―	―	―	-78.54%	10.23%
4894	33 Underperform	¥55.07B	-82.47	―	―	1242.62%	2.56%
4575	32 Underperform	¥15.77B	―	―	―	―	9.48%